XNAS · Healthcare · Biotechnology
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | Q1 2026 | -1.13 | -1.18 | -4.42% | $15,000 | ❌ Miss | +2.82% | +2.32% | — |
| 2026-05-07 | Q1 2026 | -1.13 | -1.18 | -4.42% | $15,000 | ❌ Miss | +1.98% | -2.61% | — |
| 2026-02-25 |
| Q4 2025 |
| -1.00 |
| -1.22 |
| -22.00% |
| $100,000 |
| ❌ Miss |
| -0.39% |
| -4.15% |
| -1.69% |
| 2025-11-10 | Q3 2025 | -0.89 | -1.01 | -13.48% | $0 | ❌ Miss | — | — | — |
| 2025-02-27 | Q4 2024 | -0.73 | -0.71 | +2.74% | $1.2M | ✅ Beat | +1.28% | +5.02% | -10.64% |
| 2024-11-06 | Q3 2024 | -0.68 | -0.64 | +5.88% | $3.2M | ✅ Beat | -4.20% | -2.86% | -3.11% |
| 2024-02-26 | Q4 2023 | -0.74 | -0.83 | -12.16% | $4.1M | ❌ Miss | — | — | — |
| 2023-11-02 | Q3 2023 | -0.68 | -0.81 | -19.12% | $1.5M | ❌ Miss | +8.20% | +7.37% | +33.07% |
Showing last 8 quarters.